A new mouse model mimicking thrombotic thrombocytopenic purpura: Correction of symptoms by recombinant human ADAMTS13

Blood

Volumn 119, Issue 25, 2012, Pages 6128-6135

  Schiviz, Alexandra ^a   Wuersch, Kuno ^a   Piskernik, Christina ^a   Dietrich, Barbara ^a   Hoellriegl, Werner ^a   Rottensteiner, Hanspeter ^a   Scheiflinger, Friedrich ^a   Schwarz, Hans Peter ^a   Muchitsch, Eva Maria ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; RECOMBINANT ENZYME; RECOMBINANT HUMAN ADAMTS13 PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART MUSCLE NECROSIS; HEMATOCRIT; INCIDENCE; KNOCKOUT MOUSE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84862733710     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380535     Document Type: Article

References (36)

1. Desch KC, Motto DG. Thrombotic thrombocytopenic purpura in humans and mice. Arterioscler Thromb Vasc Biol. 2007;27(9):1901-1908. (Pubitemid 47312297)
2. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116(20):4060-4069.
3. Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther. 2006;4(6): 813-825.
4. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494. (Pubitemid 32938741)
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-1594. (Pubitemid 28536133)
6. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98(6):1654-1661.
7. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factorcleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662-1666.
8. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307(23):1432-1435. (Pubitemid 13234018)
9. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005; 106(9):3035-3042. (Pubitemid 41565896)
10. Kobayashi T, Wada H, Nishioka N, et al. ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA). Thromb Res. 2008; 121(6):849-854. (Pubitemid 351491286)
11. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106(1):11-17. (Pubitemid 40967168)
12. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107(8):3161-3166.
13. Basso C, Rizzo S, Thiene G. The metamorphosis of myocardial infarction following coronary recanalization. Cardiovasc Pathol. 2010;19(1):22-28.
14. Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood. 2008; 111(7):3452-3457.
15. Huang J, Motto DG, Bundle DR, Sadler JE. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood. 2010; 116(18):3653-3659.
16. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761. (Pubitemid 41434402)
17. Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32-S38.
18. Muchitsch EM, Dietrich B, Rottensteiner H, et al. Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability. Semin Thromb Hemost. 2010;36(5):522-528.
19. Plaimauer B, Scheiflinger F. Expression and characterization of recombinant human ADAMTS-13. Semin Hematol. 2004;41(1):24-33. (Pubitemid 38057782)
20. Turecek PL, Schrenk G, Rottensteiner H, et al. Structure and function of a recombinant von Willebrand factor drug candidate. Semin Thromb Hemost. 2010;36(5):510-521.
21. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100(10):3626-3632. (Pubitemid 35303932)
22. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100. (Pubitemid 40524057)
23. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529. (Pubitemid 28506264)
24. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003;101(11):4449-4451. (Pubitemid 36857812)
25. Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2010;36(1):71-81.
26. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood. 2010;116(12):2005-2010.
27. Raife TJ. The changing paradigm of thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2005;31(6):641-651. (Pubitemid 43063082)
28. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
29. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103(4):1305-1310. (Pubitemid 38168641)
30. Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009;7(4):529-536.
31. Hawkins BM, bu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. 2008;48(2):382-392.
32. Wahla AS, Ruiz J, Noureddine N, Upadhya B, Sane DC, Owen J. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81(4):311-316.
33. McCarthy LJ, Danielson CF, Skipworth EM, Peters SL, Miraglia CC, Antony AC. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher. 2002;6(1):2-4. (Pubitemid 34218721)
34. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121(2):593-603.
35. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105(3):545-552.
36. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9(5):936-944.